Table 1.
Characteristics of study population (n = 33).
| Parameter | Total | Responders (n = 17) |
Non-Responders (n = 16) |
p Value |
|---|---|---|---|---|
| Sex no. (%) | 0.49 | |||
| Male | 14 (42.4) | 6 (35.3) | 8 (50) | |
| Female | 19 (57.6) | 11 (64.7) | 8 (50) | |
| Age (y) | 63.4 ± 11.6 | 64.1 ± 11.2 | 62.6 ± 12.2 | 0.73 |
| Body-mass index | 25.7 ± 5.4 | 26.2 ± 6.9 | 25.1 ± 3.1 | 0.85 |
| Previous therapies no. (%) | ||||
| Surgery | 21 (63.6) | 12 (70.6) | 9 (56.3) | 0.48 |
| Chemotherapy | 5(15.2) | 2 (11.8) | 3 (18.8) | 0.66 |
| Everolimus | 5 (15.2) | 2 (11.8) | 3 (18.8) | 0.66 |
| None | 8 (24.2) | 3 (17.9) | 5 (31.3) | 0.44 |
| Primary tumor site no. (%) | ||||
| Pancreas | 10 (30.3) | 4 (23.5) | 6 (37.5) | 0.46 |
| Ileum | 9 (27.3) | 8 (47.1) | 1 (6.3) | 0.02 |
| Small intestine, not otherwise specified | 6 (18.2) | 4 (23.5) | 2 (12.5) | 0.66 |
| Rectum | 2(6.1) | 0 | 2 (12.5) | 0.22 |
| Colon, not otherwise specified | 3 (9.1) | 1 (5.9) | 2 (12.5) | 0.6 |
| Unknown | 3 (9.1) | 0 | 3 (18.8) | 0.1 |
| Site of metastasis no. (%) | ||||
| Liver | 31 (93.9) | 17 (100) | 14 (87.5) | 0.23 |
| Lymph nodes | 24 (72.7) | 13 (76.5) | 11 (68.8) | 0.71 |
| Bone | 20 (60.6) | 9 (52.9) | 11 (68.8) | 0.48 |
| Other | 16 (48.5) | 8 (47.1) | 8 (50) | 1 |
| Ki-67 index no. (%) | ||||
| ≤2% (G1) | 7 (21.2) | 6 (35.3) | 1 (6.3) | 0.09 |
| 3–20% (G2) | 21 (63.6) | 11 (64.7) | 10 (62.5) | 1.00 |
| >20% (G3) | 1 (3) | 0 | 1 (6.3) | 0.48 |
| Unknown | 4 (12.1) | 0 | 4 (25.0) | 0.045 |
| Karnofsky index no. (%) | ||||
| ≤70% | 0 (0) | 0 | 0 | 1 |
| >70% | 33 (100) | 17 (100) | 16 (100) | |
| Krenning score no. (%) | ||||
| Grade 2 | 0 (0) | 0 (0) | 0 (0) | 1 |
| Grade 3 | 16 (48.5) | 8 (47.1) | 8 (50) | |
| Grade 4 | 17 (51.5) | 9 (52.9) | 8 (50) |
Values in parentheses are percentages.